Feed Top Reports Pricing

⌘K

09:04:11·71d

SECFiling

SEC Form 10-K filed by Royalty Pharma plc

RPRX· Royalty Pharma plc

Health Care

Full content unavailable. See the original source below.

Original source

Companies

RPRX
Royalty Pharma plc
Health Care

Recent analyst ratings

Jan 30UpdateUBS$49.00
Sep 30UpdateGoldman$42.00
May 16UpdateMorgan Stanley$51.00
Jun 3UpdateUBS$28.00
Jun 14UpdateUBS$47.00
May 13UpdateScotiabank$53.00

Related

PR2d
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
PR6d
Royalty Pharma Declares Second Quarter 2026 Dividend
PR8d
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
SEC10d
SEC Form 8-K filed by Royalty Pharma plc
SEC13d
SEC Form DEFA14A filed by Royalty Pharma plc
SEC13d
SEC Form DEF 14A filed by Royalty Pharma plc
INSIDER21d
SEC Form 4 filed by Coyne Terrance P.
SEC22d
SEC Form 13F-NT filed by Royalty Pharma plc

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022